ID   UACC62-RMR
AC   CVCL_A1VN
SY   UACC62 RMR; UACC62 SKIN CJ1
DR   cancercelllines; CVCL_A1VN
DR   Cell_Model_Passport; SIDM01416
DR   DepMap; ACH-002004
DR   Wikidata; Q105511311
RX   PubMed=31882401;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; GSK2118436).
CC   Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; GSK1120212).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (DepMap).
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1780 ! UACC-62
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=31882401; DOI=10.1158/0008-5472.CAN-19-2330;
RA   Melms J.C., Vallabhaneni S., Mills C.E., Yapp C., Chen J.-Y.,
RA   Morelli E., Waszyk P., Kumar S., Deming D., Moret N., Rodriguez S.,
RA   Subramanian K., Rogava M., Cartwright A.N.R., Luoma A., Mei S.-L.,
RA   Brinker T.J., Miller D.M., Spektor A., Schadendorf D., Riggi N.,
RA   Wucherpfennig K.W., Sorger P.K., Izar B.;
RT   "Inhibition of haspin kinase promotes cell-intrinsic and extrinsic
RT   antitumor activity.";
RL   Cancer Res. 80:798-810(2020).
//